Pfizer [PFE] vs Amgen [AMGN] Detailed Stock Comparison
Pfizer
NYSE
Loading...
Amgen
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Pfizer wins in 11 metrics, Amgen wins in 9 metrics, with 0 ties. Pfizer appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Pfizer | Amgen | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 12.55 | 22.33 | Pfizer |
| Price-to-Book Ratio | 1.53 | 21.63 | Pfizer |
| Debt-to-Equity Ratio | 69.70 | 756.65 | Pfizer |
| PEG Ratio | 0.00 | 0.24 | Pfizer |
| EV/EBITDA | 7.54 | 12.94 | Pfizer |
| Profit Margin (TTM) | 16.84% | 18.96% | Amgen |
| Operating Margin (TTM) | 28.68% | 32.73% | Amgen |
| EBITDA Margin (TTM) | 28.68% | 32.73% | Amgen |
| Return on Equity | 12.17% | 99.14% | Amgen |
| Return on Assets (TTM) | 5.25% | 7.51% | Amgen |
| Free Cash Flow (TTM) | $9.84B | $10.39B | Amgen |
| Dividend Yield | 5.32% | 4.09% | Pfizer |
| 1-Year Return | -5.25% | -6.96% | Pfizer |
| Price-to-Sales Ratio (TTM) | 2.12 | 4.60 | Pfizer |
| Enterprise Value | $184.71B | $208.88B | Amgen |
| EV/Revenue Ratio | 2.89 | 5.98 | Pfizer |
| Gross Profit Margin (TTM) | 74.22% | 67.20% | Pfizer |
| Revenue per Share (TTM) | $11 | $65 | Amgen |
| Earnings per Share (Diluted) | $1.90 | $13.37 | Amgen |
| Beta (Stock Volatility) | 0.46 | 0.48 | Pfizer |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Pfizer vs Amgen Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Pfizer | -0.48% | 14.75% | 8.41% | 6.95% | 9.64% | 1.77% |
| Amgen | -0.37% | 9.67% | 3.65% | 0.19% | -2.72% | 14.70% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Pfizer | -5.25% | -36.01% | -22.43% | -14.14% | 63.43% | 17.03% |
| Amgen | -6.96% | 29.85% | 25.64% | 98.81% | 427.40% | 286.13% |
News Based Sentiment: Pfizer vs Amgen
Pfizer
News based Sentiment: MIXED
Pfizer had a month of both positive developments – a major acquisition and strong Q2 earnings – and concerning headwinds, including looming patent expirations and increasing debt. The Metsera deal is a significant strategic move, but the overall investment story remains complex and requires careful monitoring.
Amgen
News based Sentiment: POSITIVE
Amgen experienced a highly positive month, driven by strong Q2 earnings that exceeded expectations, significant manufacturing investments, positive clinical trial results for Repatha leading to expanded FDA approval, and a subsequent increase in stock price. These factors collectively strengthen the investment case for Amgen.
Performance & Financial Health Analysis: Pfizer vs Amgen
| Metric | PFE | AMGN |
|---|---|---|
| Market Information | ||
| Market Cap | $147.88B | $160.11B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 50,010,390 | 3,455,190 |
| 90 Day Avg. Volume | 43,344,040 | 2,483,153 |
| Last Close | $27.08 | $297.40 |
| 52 Week Range | $20.92 - $30.43 | $253.30 - $335.88 |
| % from 52W High | -11.01% | -11.46% |
| All-Time High | $61.71 (Dec 20, 2021) | $346.85 (Jul 22, 2024) |
| % from All-Time High | -56.12% | -14.26% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.10% | 0.09% |
| Quarterly Earnings Growth | 69.98% | 0.92% |
| Financial Health | ||
| Profit Margin (TTM) | 0.17% | 0.19% |
| Operating Margin (TTM) | 0.29% | 0.33% |
| Return on Equity (TTM) | 0.12% | 0.99% |
| Debt to Equity (MRQ) | 69.70 | 756.65 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $15.60 | $13.80 |
| Cash per Share (MRQ) | $2.33 | $14.91 |
| Operating Cash Flow (TTM) | $15.19B | $12.01B |
| Levered Free Cash Flow (TTM) | $16.02B | $10.42B |
| Dividends | ||
| Last 12-Month Dividend Yield | 5.32% | 4.09% |
| Last 12-Month Dividend | $1.27 | $11.64 |
Valuation & Enterprise Metrics Analysis: Pfizer vs Amgen
| Metric | PFE | AMGN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 12.55 | 22.33 |
| Forward P/E | 8.14 | 14.44 |
| PEG Ratio | 0.00 | 0.24 |
| Price to Sales (TTM) | 2.12 | 4.60 |
| Price to Book (MRQ) | 1.53 | 21.63 |
| Market Capitalization | ||
| Market Capitalization | $147.88B | $160.11B |
| Enterprise Value | $184.71B | $208.88B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.89 | 5.98 |
| Enterprise to EBITDA | 7.54 | 12.94 |
| Risk & Other Metrics | ||
| Beta | 0.46 | 0.48 |
| Book Value per Share (MRQ) | $15.60 | $13.80 |
Financial Statements Comparison: Pfizer vs Amgen
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PFE | AMGN |
|---|---|---|
| Revenue/Sales | $14.65B | $8.15B |
| Cost of Goods Sold | $3.78B | $2.97B |
| Gross Profit | $10.88B | $5.18B |
| Research & Development | $2.48B | $1.49B |
| Operating Income (EBIT) | $3.77B | $1.18B |
| EBITDA | $5.75B | $4.08B |
| Pre-Tax Income | $3.04B | $1.97B |
| Income Tax | $141.00M | $243.00M |
| Net Income (Profit) | $2.93B | $1.73B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PFE | AMGN |
|---|---|---|
| Cash & Equivalents | $1.43B | $8.81B |
| Total Current Assets | $45.86B | $26.93B |
| Total Current Liabilities | $36.45B | $23.01B |
| Long-Term Debt | $56.82B | $54.01B |
| Total Shareholders Equity | $90.64B | $6.21B |
| Retained Earnings | $119.59B | $-27.14B |
| Property, Plant & Equipment | N/A | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PFE | AMGN |
|---|---|---|
| Operating Cash Flow | $3.91B | $1.71B |
| Capital Expenditures | $-564.00M | $-411.00M |
| Free Cash Flow | $1.77B | $980.00M |
| Debt Repayment | $-2.43B | $-2.50B |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | PFE | AMGN |
|---|---|---|
| Shares Short | 112.93M | 13.20M |
| Short Ratio | 2.85 | 6.63 |
| Short % of Float | 0.02% | 0.02% |
| Average Daily Volume (10 Day) | 50,010,390 | 3,455,190 |
| Average Daily Volume (90 Day) | 43,344,040 | 2,483,153 |
| Shares Outstanding | 5.67B | 537.00M |
| Float Shares | 5.68B | 536.99M |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.67% | 0.84% |
Dividend Analysis & Yield Comparison: Pfizer vs Amgen
| Metric | PFE | AMGN |
|---|---|---|
| Last 12-Month Dividend | $1.27 | $11.64 |
| Last 12-Month Dividend Yield | 5.32% | 4.09% |
| 3-Year Avg Annual Dividend | $1.52 | $9.51 |
| 3-Year Avg Dividend Yield | 1.27% | 0.80% |
| 3-Year Total Dividends | $4.55 | $28.54 |
| Ex-Dividend Date | Jan 24, 2025 | Aug 22, 2025 |